CHKA and cancer: Furthermore, kinases that are MOA targets for approved drugs have significantly higher average and median CKI scores than non-MOA targets across all cancers (p < 0.0001) (p < 0.05 for select cancer cohorts; Data S2A–S2N; Table S2).